| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 7 | |
| #2 | Canada | 5 | |
| #3 | EPO (European Patent Office) | 5 | |
| #4 | WIPO (World Intellectual Property Organization) | 4 | |
| #5 | Australia | 2 | |
| #6 | Republic of Korea | 2 | |
| #7 | China | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Organic fine chemistry |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Medical preparations | |
| #3 | Peptides | |
| #4 | Special acyclic compounds |
| # | Name | Total Patents |
|---|---|---|
| #1 | Mctavish Hugh | 26 |
| #2 | Dudek Arkadiusz Z | 5 |
| #3 | Dudek Arkadiusz | 2 |
| Publication | Filing date | Title |
|---|---|---|
| US2018333501A1 | Insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome | |
| CN110636867A | Insulin-like growth factor-chemotherapeutic conjugates for the treatment of myelodysplastic syndrome | |
| CA2936675A1 | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof | |
| WO2006047214A2 | Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer | |
| CA2542834A1 | Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents |